Phospho-EIF4EBP1 (Thr70) Antibody

What is the biological role of EIF4EBP1 Thr70 phosphorylation in translation regulation?

Phosphorylation of EIF4EBP1 at Thr70 plays a critical role in the hierarchical phosphorylation cascade that regulates cap-dependent translation. EIF4EBP1 (also known as 4E-BP1) functions as a translation inhibitor by binding to eIF4E, preventing the assembly of the eIF4F translation initiation complex. The phosphorylation at Thr70 occurs as an intermediate step in a sequential process where Thr37/Thr46 phosphorylation serves as a priming event, followed by Thr70 phosphorylation, and finally Ser65 phosphorylation . This ordered phosphorylation contributes to the gradual release of EIF4EBP1 from eIF4E, thereby enabling cap-dependent translation to proceed .

How does the phosphorylation hierarchy of EIF4EBP1 operate, and what is Thr70's position in this cascade?

EIF4EBP1 phosphorylation follows a strict hierarchical order that has been established through rigorous phosphopeptide mapping and mass spectrometry analyses. The phosphorylation process begins with the priming phosphorylation of Thr37 and Thr46, which occurs even in serum-starved conditions and is mediated primarily by mTORC1 . Following this priming step, Thr70 phosphorylation takes place as an intermediate event, which is then followed by Ser65 phosphorylation . This sequential order is critical, as each phosphorylation event prepares the molecule for subsequent modifications. Importantly, studies have shown that phosphorylation of Thr70 alone, or even in combination with Ser65, is insufficient to disrupt EIF4EBP1 binding to eIF4E, indicating that the complete phosphorylation cascade is necessary for effective translational activation .

What distinguishes the mTOR-mediated regulation of Thr70 phosphorylation from other phosphorylation sites?

The mTOR-mediated regulation of Thr70 phosphorylation exhibits distinct characteristics compared to other phosphorylation sites on EIF4EBP1. While mTOR directly mediates the phosphorylation at Thr37 and Thr46 sites as priming events, it also impacts the phosphorylation at Thr70 and Ser65 . A key distinguishing feature is that Thr70 phosphorylation demonstrates higher sensitivity to rapamycin (an mTOR inhibitor) compared to Thr37/Thr46 phosphorylation . This differential sensitivity suggests that while mTOR activity is necessary for all these phosphorylation events, the mechanisms and possibly the kinase complexes involved may differ. Research has also demonstrated that overexpression of rapamycin-insensitive mTOR can result in EIF4EBP1 phosphorylation even in the presence of rapamycin, further supporting the central role of mTOR in this regulatory process .

What are the optimal methods for detecting Phospho-EIF4EBP1 (Thr70) in different experimental systems?

Detection of Phospho-EIF4EBP1 (Thr70) requires careful methodological consideration based on the experimental system. Western blotting represents the primary method, with recommended antibody dilutions of 1:1000 . For more specific applications, immunoprecipitation can be performed using a 1:50 dilution . When analyzing phosphorylation patterns, two-dimensional techniques combining isoelectric focusing with SDS-PAGE provide superior resolution of the various phosphorylated species of EIF4EBP1 . This approach, followed by Western blotting with phospho-specific antibodies, allows unambiguous determination of the phosphorylation state and sequence of events.

For cellular localization studies, particularly in reproductive biology research, immunofluorescence microscopy using specific anti-phospho-Thr70-EIF4EBP1 polyclonal antibodies has been successfully employed . When comparing multiple phosphorylation sites simultaneously, it's crucial to select antibodies with demonstrated specificity, such as the well-characterized antibodies against EIF4EBP1, phospho-Thr70-EIF4EBP1, and phospho-Ser65-EIF4EBP1 .

How can researchers distinguish between different phosphorylated states of EIF4EBP1 in complex biological samples?

Distinguishing between different phosphorylated states of EIF4EBP1 in complex biological samples requires sophisticated analytical approaches. The gold standard involves a combination of two-dimensional electrophoresis techniques followed by Western blotting with phosphosite-specific antibodies . This method separates EIF4EBP1 first by isoelectric point (reflecting total phosphorylation state) and then by molecular weight, generating a characteristic pattern where each phosphorylated species occupies a distinct position.

For more precise quantitative analysis, mass spectrometry following immunoprecipitation provides detailed phosphopeptide mapping that can identify the exact residues carrying phosphate groups . This approach has been instrumental in establishing the hierarchical nature of EIF4EBP1 phosphorylation, revealing that phosphorylation at Thr37/Thr46 appears first, followed by Thr70, and finally Ser65 .

When analyzing multiple samples or performing high-throughput studies, researchers have also employed phosphorylation-specific antibodies in array formats or ELISA-based methods to monitor specific phosphorylation events while maintaining reasonable throughput capability.

What controls should be included when validating Phospho-EIF4EBP1 (Thr70) antibody specificity?

Rigorous validation of Phospho-EIF4EBP1 (Thr70) antibody specificity requires multiple complementary controls. The following validation strategy ensures reliable experimental outcomes:

Additionally, researchers should verify that the antibody recognizes the correct molecular weight range (15-20 kDa for EIF4EBP1) and produces minimal background in the experimental system. For quantitative applications, establishing a standard curve with recombinant phosphorylated protein is recommended to ensure linearity in the working range.

How does Thr70 phosphorylation status correlate with cancer progression and therapeutic response?

The phosphorylation status of EIF4EBP1 at Thr70 demonstrates significant correlations with cancer progression and therapeutic response across multiple malignancies. In malignant melanoma, higher levels of EIF4EBP1 phosphorylation at Thr70 (pT70) are associated with worse prognosis . This pattern reflects the broader role of dysregulated cap-dependent translation in cancer progression.

Distinct cancer types exhibit varying patterns of EIF4EBP1 phosphorylation, with phosphorylation at different sites (T37/46, T70, and S65) showing considerable variation among different cancer cell lines and clinical specimens . The prognostic significance of EIF4EBP1 phosphorylation appears to be cancer-type specific, with some studies reporting contradictory findings. For instance, while increased 4EBP1 protein levels correlate with poor survival in hepatocellular carcinoma, elevated phospho-4EBP1 has been associated with prolonged survival in gastric cancer patients .

The therapeutic implications are substantial, as many targeted therapies, particularly mTOR inhibitors, directly affect EIF4EBP1 phosphorylation. Thr70 phosphorylation demonstrates higher sensitivity to rapamycin than Thr37/Thr46 phosphorylation , suggesting that monitoring pT70 levels could serve as a more sensitive biomarker for mTOR inhibitor efficacy in clinical settings.

What is the mechanistic difference between Thr70 phosphorylation and other phosphorylation sites in regulating EIF4EBP1 function?

The mechanistic distinction between Thr70 phosphorylation and other phosphorylation sites lies in their structural and functional impacts on EIF4EBP1. Structurally, EIF4EBP1 contains several important motifs: a central eIF4E-binding motif (residues 54-60), a priming region containing Thr37/Thr46 adjacent to motif 1, and motif 2 which is a proline-turn-helix segment containing Ser65 and Thr70 phosphorylation sites .

Functionally, phosphorylation at Thr37/Thr46 by mTORC1 serves as a priming event that does not directly prevent binding to eIF4E . These priming phosphorylations induce conformational changes that facilitate subsequent phosphorylation at Thr70 and then Ser65. Importantly, research has demonstrated that phosphorylation of Thr70 alone, or even in combination with Ser65, is insufficient to completely disrupt EIF4EBP1 binding to eIF4E . This indicates that the full phosphorylation cascade, involving all key sites, works cooperatively to modulate EIF4EBP1's inhibitory function.

The hierarchical nature of these phosphorylation events suggests that Thr70 occupies a critical intermediate position in the regulatory cascade. Its phosphorylation represents a committed step following the priming events but preceding the final modifications that ultimately lead to eIF4E release and translation activation.

How can phosphoproteomic approaches be optimized for studying Thr70 phosphorylation dynamics in different cellular contexts?

Optimizing phosphoproteomic approaches for studying Thr70 phosphorylation dynamics requires tailored strategies that address the specific challenges of EIF4EBP1 analysis:

• Cellular Context Considerations: When comparing different cellular contexts (e.g., different tissues or cell lines), it's essential to normalize phosphorylation levels to total EIF4EBP1 expression, which can vary substantially between tissue types . Additionally, researchers should consider the activation status of upstream signaling pathways, particularly PI3K/Akt/mTOR, which directly influence EIF4EBP1 phosphorylation patterns.

What are the common challenges in detecting Phospho-EIF4EBP1 (Thr70) and how can they be addressed?

Detecting Phospho-EIF4EBP1 (Thr70) presents several technical challenges that require specific troubleshooting approaches:

• Low Signal Intensity: EIF4EBP1 is relatively low abundance in many cell types. To improve detection:

  • Increase protein loading (50-100 μg total protein recommended)

  • Optimize lysis conditions using phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and β-glycerophosphate)

  • Consider using signal enhancement systems for Western blotting

• Phosphatase Activity During Sample Preparation: Rapid dephosphorylation can occur during cell lysis. To prevent this:

  • Process samples rapidly at 4°C

  • Use freshly prepared lysis buffers with comprehensive phosphatase inhibitor cocktails

  • Consider direct lysis in hot SDS-PAGE sample buffer for immediate denaturation of phosphatases

• Antibody Cross-Reactivity: Phospho-antibodies may recognize similar phosphoepitopes. To ensure specificity:

  • Validate with phosphopeptide competition assays

  • Include appropriate controls (phosphatase-treated samples, T70A mutants)

  • Consider using antibodies specifically validated for your species of interest (human, mouse, rat, or monkey)

• Background Signals: High background can mask specific signals. To minimize this:

  • Optimize blocking conditions (5% BSA often performs better than milk for phospho-epitopes)

  • Increase washing duration and detergent concentration

  • Titrate primary antibody concentration (starting with 1:1000 dilution)

How should experimental conditions be modified to study Thr70 phosphorylation in different cell types and states?

Studying Thr70 phosphorylation across different cell types and states requires tailored experimental approaches:

• Cell-Type Specific Considerations:

  • For highly proliferative cells (cancer cell lines): Standard serum starvation (16-24h) followed by stimulation is usually sufficient

  • For primary cells: Gentler serum reduction (to 0.5-1%) may be necessary to maintain viability

  • For post-mitotic cells (neurons, myotubes): Consider specialized stimulation protocols targeting nutrient-sensing pathways

• Stimulation Protocols:

  • Growth factor stimulation: 10% serum, insulin (100nM), or EGF (100ng/ml) for 30-60 minutes

  • Nutrient stimulation: Amino acid readdition after starvation (particularly leucine)

  • Stress conditions: Hypoxia, ER stress, or oxidative stress may differentially affect Thr70 phosphorylation

• Inhibitor Studies:

  • mTOR inhibition: Rapamycin (100nM) or Torin1 (250nM) treatments reveal mTOR-dependency

  • PI3K inhibition: Wortmannin (100nM) or LY294002 (10μM) reveal upstream pathway requirements

  • MEK inhibition: U0126 (10μM) to assess MAPK pathway contributions

• Timing Considerations:

  • Short-term dynamics: Sample at 5, 15, 30, 60 minutes post-stimulation

  • Long-term regulation: Extend to 2, 4, 8, 24 hours for adaptive responses

  • Cell cycle studies: Synchronize cells and sample at defined cell cycle phases

When comparing results across different cell types, normalize phospho-Thr70 signals to total EIF4EBP1 levels, as basal expression can vary significantly between tissues and cell lines .

What are the critical considerations when designing experiments to assess the functional consequences of Thr70 phosphorylation?

Designing experiments to assess functional consequences of Thr70 phosphorylation requires careful consideration of multiple factors:

• Genetic Manipulation Approaches:

  • Site-specific mutants: T70A (phospho-null) and T70E/T70D (phosphomimetic) mutations

  • Expression system selection: Transient vs. stable expression; consider doxycycline-inducible systems for controlled expression

  • Endogenous modification: CRISPR/Cas9 knock-in of point mutations preserves physiological expression levels

• Functional Readouts:

  • Direct binding assays: m⁷GTP pull-down assays to quantify EIF4EBP1-eIF4E interaction

  • Translation assays: Polysome profiling, SUnSET (puromycin incorporation), or luciferase reporters

  • Cellular phenotypes: Proliferation, cell size, migration, or stress resistance depending on cell type

• Multi-site Phosphorylation Considerations:

  • Generate combined mutants (e.g., T37/46A+T70A or T70A+S65A) to address hierarchical requirements

  • Use phospho-specific antibodies to confirm effects on other phosphorylation sites

  • Consider rapamycin treatment to distinguish mTOR-dependent from independent effects

• Context Dependency:

  • Normal vs. stress conditions (nutrient limitation, hypoxia, ER stress)

  • Cell cycle phase (particularly important given links to mitotic regulation)

  • Growth factor and nutrient availability

• Controls and Validation:

  • Include wild-type EIF4EBP1 as positive control

  • Use non-phosphorylatable 4A mutant (T37A/T46A/S65A/T70A) as negative control

  • Verify mutant protein stability and expression levels match wild-type

Remember that while Thr70 phosphorylation is an important regulatory event, it functions within a broader phosphorylation cascade. The full functional consequences may only be apparent when considering the complete sequence of phosphorylation events that collectively regulate EIF4EBP1's interaction with eIF4E .

How does Thr70 phosphorylation connect to cellular processes beyond translation control?

Emerging research reveals that Thr70 phosphorylation of EIF4EBP1 extends beyond canonical translation control to influence diverse cellular processes. One significant connection is to cell cycle regulation, particularly during mitosis. Studies have identified that phosphorylated EIF4EBP1 localizes to maternal mRNA at the spindle in oocytes, suggesting a role in coupling cell cycle progression to localized mRNA translation . This finding indicates that EIF4EBP1 may serve as an integrator that coordinates translation with proper chromosomal segregation during cell division.

Additionally, the interaction between phosphorylated EIF4EBP1 and the cancer microenvironment represents an emerging area of investigation. Research suggests that 4EBP1-driven cancer-associated fibroblast (CAF) infiltration correlates with cancer prognosis, indicating that phosphorylation status may influence tumor-stromal interactions . This presents a novel perspective on how translation regulators might shape the tumor microenvironment beyond their direct effects on cancer cell protein synthesis.

The evolutionary conservation of these mechanisms between mammals and other vertebrates, as well as their presence in various cell types, suggests that Thr70 phosphorylation of EIF4EBP1 may be part of a fundamental cellular process that integrates translation control with other critical cellular functions .

What are the latest technological advances for monitoring EIF4EBP1 Thr70 phosphorylation dynamics in live cells?

Recent technological advances have revolutionized the ability to monitor EIF4EBP1 Thr70 phosphorylation dynamics in live cells:

• Genetically Encoded Biosensors: FRET-based biosensors that incorporate EIF4EBP1 domains can detect phosphorylation-induced conformational changes in real-time. These biosensors typically sandwich EIF4EBP1 between fluorescent proteins, allowing visualization of phosphorylation events through changes in FRET efficiency.

• Phosphorylation-sensitive Fluorescent Proteins: Modified GFP variants with phospho-binding domains (like FHA or 14-3-3) coupled to EIF4EBP1 sequences can provide direct readouts of phosphorylation status through subcellular relocalization or spectral shifts.

• Single-molecule Tracking: Techniques combining PALM/STORM super-resolution microscopy with site-specific labeling allow researchers to track individual EIF4EBP1 molecules and their interactions with translation machinery components following phosphorylation.

• Cell-permeable Fluorescent Probes: Phospho-specific antibody fragments conjugated to cell-penetrating peptides and fluorophores permit visualization of endogenous phospho-Thr70 without genetic manipulation.

• Proximity Ligation Assays: Modified for live-cell applications, these techniques can visualize the interaction between phosphorylated EIF4EBP1 and its binding partners as discrete fluorescent puncta.

These methodologies offer distinct advantages for different experimental questions, with the appropriate choice depending on temporal resolution requirements, preference for endogenous vs. exogenous protein analysis, and the specific cellular context under investigation.

How might targeting Thr70 phosphorylation specifically offer therapeutic advantages over general mTOR inhibition?

Targeting Thr70 phosphorylation specifically could present several therapeutic advantages over general mTOR inhibition:

• Pathway Selectivity: While general mTOR inhibitors affect multiple downstream targets, Thr70-specific interventions would selectively impact the translation regulation arm of mTOR signaling. This could potentially reduce off-target effects associated with comprehensive mTOR inhibition, which affects processes including autophagy, lipid metabolism, and cell growth.

• Differential Sensitivity: Research has demonstrated that Thr70 phosphorylation shows greater sensitivity to rapamycin than other phosphorylation sites like Thr37/46 . This differential sensitivity suggests that Thr70-focused interventions might provide a more tunable approach to modulating cap-dependent translation in therapeutic settings.

• Cancer-specific Applications: In malignancies where higher levels of Thr70 phosphorylation correlate with worse prognosis, such as melanoma , targeted interventions against this specific phosphorylation event could provide precision therapy with potentially fewer systemic side effects.

• Combinatorial Potential: Thr70-specific targeting could be strategically combined with other therapies that affect different aspects of translation control or parallel signaling pathways. For instance, combining Thr70-directed therapy with agents that target eIF4E directly might produce synergistic effects in blocking aberrant translation while maintaining essential cellular functions.

• Biomarker Development: The phosphorylation status of Thr70 could serve as a biomarker for therapy selection and monitoring response, potentially enabling more personalized treatment approaches based on the specific phosphorylation profile of individual tumors.